The largest pharmaceutical market in the GCC: size and growth, public procurement through NUPCO, SFDA registration and pricing, localisation targets and local manufacturers, generics and biosimilars, and the implications for suppliers.
Saudi Arabia is the largest pharmaceutical market in the GCC. Published estimates for 2025 range from USD 9.6 bn to USD 15.1 bn; our central estimate is USD 12.5 bn, growing at about 7% to USD 20.1 bn by 2032. The public sector — Ministry of Health clusters, military and university hospitals — buys through NUPCO’s centralised tenders; the private sector buys through distributors and group contracts; CCHI-insured volume is growing fastest.
Two policies dominate supplier strategy: SFDA registration and pricing (with international reference pricing), and localisation — targets for domestically manufactured medicines, incentives for local plants (SPIMACO, Tabuk, Jamjoom, Riyadh Pharma, Sudair Pharma, new biologics JVs) and NUPCO preference for local products. The RSD track-and-trace system applies to all packs.
The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 9.6 bn–USD 15.1 bn; differences are mostly scope.
| Publisher (date) | Base value | Forecast | CAGR |
|---|---|---|---|
| IQVIA Market Prognosis 2025-2029 (via CPHI Middle East market report) (2025-09) — Ex-manufacturer invoice prices, excluding rebates/discounts | None (2024) | SAR 83.3 bn (~USD 22.2 bn) (2029) | 10.8% (±2.8%) 2024-2029 |
| Oliver Wyman (2026-08) — Largest pharma market in MENA; up from USD 8-9 bn in 2021; g | USD 14-16 bn (2024) | — () | — |
| Credence Research (2025-09) — Branded 54% / generic 36% / biosimilars 10% (2024) | USD 12.04 bn (2024) | USD 21.16 bn (2032) | 6.80% |
| IMARC Group (2026-09) — Conservative estimate; 2026E USD 9.83 bn; prescription drugs | USD 9.60 bn (2025) | USD 11.79 bn (2034) | 2.30% (2026-2034) |
| MarketScreener (citing SFDA / Vision 2030) (2026-05) — Drug spend; 55+ licensed factories; local manufacturers cove | USD 10-12 bn annual drug spend (2025) | — () | — |
| ResearchAndMarkets (Saudi Arabia Generic Drugs Market Outlook 2025-2033) (2025-08) — Generic drugs segment only, not total pharma | USD 4.05 bn (generics only) (2024) | USD 8.11 bn (generics only) (2033) | 8.02% (2025-2033) |
| Consulting Wallah central estimate | USD 12.5 bn (2025) | USD 20.1 bn (2032) | ~7% |
Source: Publisher pages as listed under Sources; CW estimate as described in Method.
Included: prescription, OTC, biologics and vaccines across public and private channels. Excluded: devices, nutrition. Institutions: SFDA, NUPCO, Ministry of Health and health clusters, CCHI, Health Holding Company, Ministry of Industry (localisation).
Shares as reported by the named sources; ranking is more reliable than the exact percentage.
| Segment | Share | Note | |
|---|---|---|---|
| Branded | 54% | ||
| Generic | 36% | ||
| Biosimilars | 10% |
Source: Credence Research
| Segment | Share | Note | |
|---|---|---|---|
| Prescription drugs | 63% | ||
| OTC | 18% | ||
| Vaccines | 12% | ||
| Dietary supplements | 7% |
Source: Credence Research
| Segment | Share | Note | |
|---|---|---|---|
| Oncology | 29% | ||
| Cardiology | 21% | ||
| Diabetes | 17% | ||
| Neurology | 12% | ||
| Respiratory | 9% |
Source: Credence Research
| Segment | Share | Note | |
|---|---|---|---|
| Central | 38% | ||
| Western | 27% | ||
| Eastern | 22% | ||
| Southern | 13% |
Source: Credence Research
| Segment | Share | Note | |
|---|---|---|---|
| Generics | 37% | 'nearly 40%' |
Source: Oliver Wyman
| Segment | Share | Note | |
|---|---|---|---|
| Local production share of drug consumption | 26.3% | Vision 2030 Health Sector Transformation Report 2025 | |
| Local manufacturers share of demand | 20% | SFDA/Vision 2030 via MarketScreener |
Source: Oliver Wyman / MarketScreener
| Segment | Share | Note | |
|---|---|---|---|
| Retail pharmacy | 57% |
Source: IMARC Group
| Country / region | Figure | Year | Source |
|---|---|---|---|
| Saudi pharma exports | USD 579.6 mn (UN Comtrade) | 2024 | IQVIA / CPHI |
| Saudi healthcare budget | SAR 260 bn (>20% of total budget) | 2025 | IQVIA / CPHI |
| NUPCO annual procurement | > SAR 25 bn | 2025 | Argaam |
| Licensed pharma factories in KSA | 55+ | 2026 | MarketScreener (SFDA) |
| Health insurance coverage | 13.0 mn individuals | 2025-01 | IQVIA / CPHI |
Source: Sources as named; see Sources and method.
NUPCO runs multi-year frameworks and a national logistics network; private groups (Al Habib, Mouwasat, Dallah) tender separately; Nahdi and Al Dawaa dominate retail. Biosimilar uptake is accelerating in public tenders; generics share is rising under pricing reform.
India is a top source of generics and increasingly of biosimilars and APIs for Saudi Arabia; localisation favours Indian firms willing to set up Saudi plants or JVs (several announced 2023–25). SFDA GMP inspection of Indian plants is the practical gate.
| Date | Development | Source |
|---|---|---|
| 2026-08 | Oliver Wyman: Saudi pharma market USD 14-16 bn (2024), generics ~38%; local production share rose to 30.5% in 2024 from 26.3% in 2019. | Oliver Wyman |
| 2026-05 | Jamjoom Pharma reported FY25 revenue SAR 1.5 bn (+13.8%) and net profit SAR 463.8 mn (+30%); plans 57 new products. | MarketScreener |
| 2025-07 | Pharmacy Saudization quotas introduced: 35% community, 65% hospital, 55% general pharmacy. | IQVIA / CPHI |
| 2025-06 | SFDA issued a biosimilar quality guideline; LCGPA expanded the list of pharmaceuticals eligible for local-content price preference. | IQVIA / CPHI |
| 2025-02 | NUPCO signed SAR 2.5 bn supplier-financing agreements (BSF SAR 500 mn, FAB KSA SAR 1 bn, Tameed SAR 1 bn) and said annual procurement exceeds SAR 25 bn. | Argaam |
| 2025-02 | LCGPA added 17 pharmaceuticals to the mandatory local-content list with 30% price preference. | IQVIA / CPHI |
Source: Company and press announcements as named.
Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.
Published estimates normalised to 2025 range from USD 9.6 bn to USD 15.1 bn. Consulting Wallah’s central estimate is USD 12.5 bn in 2025, rising to about USD 20.1 bn by 2032.
Published CAGRs range from 2.3% to 6.8%; our central case is about 7% a year to 2032.
SPIMACO, Tabuk Pharmaceuticals (ASTRA Industrial), Jamjoom Pharma, Riyadh Pharma, Sudair Pharma, Lifera (PIF), Aja Pharma, Saudi Arabian Japanese Pharmaceuticals (SAJA) among others.
The summary on this page is free to read and share with attribution. The full report is free for hospital leaders and registered Consulting Wallah Network members, and priced on request for others.
The full report (PDF, 40 pages) adds the GCC and India deep-dives, hospital-level benchmarks from the Consulting Wallah Network and the full source tables. Free for hospital leaders and registered network members; otherwise priced on request.
How to read these figures. Published market-size estimates for this market vary widely because publishers define scope differently (software only vs software + services + logistics). Where we show a Consulting Wallah estimate we state the range of published figures it is triangulated from and our scope. Figures marked as reported are quoted from the named source. Nothing here is investment advice.